SYNGAP1 Legislative Advocacy
Buchanan, Ingersoll, and Rooney PC, on behalf of the SYNGAP1 Foundation, will provide pro bono services to develop and execute a government relations strategy aligning SYNGAP1's agenda with the current environment in Washington, D.C.
HON. MICHAEL T. McCAUL
of Texas in the House of Representatives
Thursday, July 14, 2016
This program is a crucial incentive--in addition to the Orphan Drug Act--for drug manufacturers to invest significantly in developing therapies for rare pediatric diseases, including pediatric cancers and lysosomal storage disorders.